Skip to main content
SpringerLink
Log in

Anti-TNF access criteria improve cost-effective use in SpA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study received financial support from Pfizer Ltd., France.

Reference

  • Harvard S, et al. Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. Cost Effectiveness and Resource Allocation : 7 Sep 2017. Available from: URL: https://doi.org/10.1186/s12962-017-0081-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-TNF access criteria improve cost-effective use in SpA. PharmacoEcon Outcomes News 787, 6 (2017). https://doi.org/10.1007/s40274-017-4334-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4334-8

Search

Navigation